4 Blue-Chip Dividend Stocks That Could Turn $200,000 Into Annual Retirement Income24/7 Wall Street • Tuesday
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial CancerBusiness Wire • Monday
LLY vs. MRK: Which Stock Offers the More Compelling Investment Case?Zacks Investment Research • Monday
Countdown to Merck (MRK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • Monday
Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 2924/7 Wall Street • 10/25/26
Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?Investors Business Daily • 10/23/26
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fallCNBC • 10/23/26
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip24/7 Wall Street • 10/23/26
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential SymposiumBusiness Wire • 10/22/26
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare TumorsBusiness Wire • 10/21/26
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)Business Wire • 10/21/26
Arcus Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer DataInvestors Business Daily • 10/20/26